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Objectives This study sought to compare survival of patients with poorly compressible arteries (PCA) to those with a normal
ankle-brachial index (ABI) and those with peripheral arterial disease (PAD).
Background Limited data are available regarding survival in patients with PCA identified in the clinical setting by noninvasive
lower extremity arterial evaluation.
Methods We conducted a historical cohort study of consecutive patients who underwent outpatient, noninvasive lower
extremity arterial evaluation at the Mayo Clinic, Rochester, Minnesota, from January 1998 through December
2007, and who were followed for a mean duration of 5.8  3.1 years. An ABI 1.00 to 1.30 was considered nor-
mal, PAD was defined as a resting or post-exercise ABI 0.90, and PCA defined as an ABI 1.4 and/or an an-
kle systolic blood pressure 255 mm Hg. Patients were followed for all-cause mortality through September 30,
2009.
Results Of 16,493 individuals (mean age 67.8  13.0 years, 59% male); 29% had normal ABI, 54% had PAD, and 17%
had PCA. During follow-up (mean duration 5.8  3.1 years), 4,365 patients (26%) died. The percent alive at the
end of the study period was 88%, 70%, and 60% for normal ABI, PAD, and PCA, respectively. After adjustment
for age, sex, cardiovascular risk factors, comorbid conditions, and medication use, the hazard ratios (95% confi-
dence intervals) of death associated with PCA were 2.0 (1.8 to 2.2) and 1.3 (1.2 to 1.4) compared with the nor-
mal ABI and PAD groups, respectively.
Conclusions Patients identified by noninvasive vascular testing to have poorly compressible leg arteries have poor survival,
worse than those with a normal ABI or those with PAD. (J Am Coll Cardiol 2012;59:400–7) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.055Patients with known or suspected lower extremity periph-
eral artery disease (PAD) are typically evaluated in the
outpatient setting by measuring the ankle-brachial index
(ABI), the ratio of the lower of the ankle systolic blood
pressures (BP) at each ankle to the higher arm systolic BP
(1). An ABI between 1.00 and 1.30 is considered normal,
and an ABI 0.90 indicates the presence of PAD (2). An
ABI 1.40 is abnormal and a consequence of medial
arterial calcification (3) in the lower extremities leading to
poor compressibility or “stiffness” of the arteries. As a result,
higher cuff pressure is needed to cause compression or
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2011, accepted September 27, 2011.occlusion of the arteries, resulting either in an inability to
obtain an ABI (ankle BP 255 mm Hg) or a falsely
elevated ABI (1.40) (4). The presence of poorly compress-
ible arteries (PCA) in the lower extremities has been found
to be highly specific for calcification of the medial layer in
these arteries (4–6). The phenomenon has also been re-
ferred to in the literature as “calcified,” “stiff,” “non com-
pressible,” or “poorly compressible” vessels/arteries. In this
report, we use the term “poorly compressible arteries.”
See page 408
According to data from the National Health and Nutri-
tional Examination Survey, 1.6 million adults age40 years
in the United States have an ABI 1.40 (7). These
individuals have a higher prevalence of diabetes, chronic
kidney disease, and cardiovascular disease, and lower quality
of life than those with normal ABI (8–10). Three previous
studies (11–13) of random samples of community-dwelling
volunteers have shown that participants with a high ABI
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Other than small studies (n  8 and 403, respectively)
(14,15), limited data are available regarding survival of
patients identified in the clinical setting as having PCA.
The goal of the present study was to compare patients
with PCA identified in the noninvasive vascular laboratory
to patients with a normal ABI, as well as to patients with
PAD, in terms of prevalence of cardiovascular risk factors,
comorbid conditions, and survival. We estimated survival
free of death and identified predictors of survival in patients
undergoing noninvasive lower extremity arterial evaluation
in the outpatient setting. Knowledge of life expectancy may
be useful in the care of patients with PCA by informing
clinical decision-making.
Methods
Study design and population. This study used a historical
cohort design. The sample consisted of consecutive adult
patients who underwent outpatient lower extremity arterial
evaluation for suspected or known PAD in the noninvasive
vascular laboratory of the Mayo Clinic, Rochester, Minne-
sota, between January 1, 1998, and December 31, 2007.
Since January of 1998, the results of all noninvasive lower
extremity arterial evaluations have been entered into a
database that becomes part of the Mayo electronic medical
record (EMR). We excluded patients who: 1) refused
research authorization; 2) had missing results of arterial
evaluation; 3) resided outside a 500-mile radius of Roches-
ter, Minnesota; 4) were hospitalized at the time of arterial
evaluation; and 5) were aged 18 years at the time of
arterial evaluation (Fig. 1). Additionally, to ease interpreta-
tion of analyses, we excluded patients with borderline high
ABI (1.31 to 1.39) and borderline low ABI (0.91 to 0.99)
(Fig. 1).
Noninvasive lower extremity arterial evaluation. Lower
extremity arterial evaluation was performed using standard-
ized protocols in the noninvasive vascular laboratory, which
is certified by the Intersocietal Commission for the Accred-
itation of Vascular Laboratories. Systolic BP was measured
in each arm and in the dorsalis pedis and posterior tibial
arteries bilaterally using a hand-held 8.3-MHz Doppler
probe. The higher of the 2 arm pressures and the lower of
the 2 ankle pressures were used to calculate the ABI in each
leg. The ABI based on the lower ankle pressure identifies a
greater number of patients at risk for adverse cardiovascular
events than an ABI based on the higher ankle pressure (16).
However, since the latter has been used for calculating the
ABI in several prior studies, we also performed analyses
based on the higher ankle pressure (results provided in the
Online Appendix) to facilitate comparison to these studies.
A standard treadmill test with a speed of 1 to 2 mph and a
fixed grade of 10° with continuous electrocardiographic
monitoring is performed (except in patients with severe
PAD, i.e., ABI 0.5, and in patients with PCA) to obtain
post-exercise ABI. Doppler waveforms were recorded fromeach major lower extremity ar-
tery. The data were interpreted
and reported by a vascular med-
icine specialist.
Definition of normal ABI,
PAD, and PCA. We defined
normal ABI as 1.0 to 1.3, bor-
derline low ABI as 0.91 to 0.99,
and borderline high ABI as 1.31
to 1.39. We defined PAD as an
ABI 0.9 at rest or 1 min after
exercise. Since patients with
PAD can have a normal ABI
after revascularization, we used
International Classification of
Diseases, Ninth Revision, Clini-
cal Modification (ICD-9-CM)
procedure codes for surgical or
percutaneous revascularization
supplemented by manual review
of medical records, to identify
such individuals. Patients were
classified as having PCA if any
ABI was 1.40 or the ankle systolic BP was 255 mm Hg
(upper limit of commonly used BP apparatuses) or the term
“noncompressible vessels” was mentioned in the lower
extremity arterial evaluation. In patients with PCA, we
additionally ascertained whether abnormal Doppler wave-
forms (absent, monophasic, or reduced biphasic) in a lower
extremity artery had been noted during the laboratory
evaluation.
Cardiovascular risk factors and comorbid conditions.
Demographic characteristics including area of residence and
ethnicity, height, and weight were obtained from the Mayo
EMR, which contains both structured and free-text ele-
ments. Cardiovascular risk factors were ascertained from the
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
BP  blood pressure
CHD  coronary heart
disease
CI  confidence interval
EMR  electronic medical
record
HR  hazard ratio
ICD-9-CM  International
Classification of Diseases-
Ninth Revision-Clinical
Modification
NLP  natural language
processing
PAD  peripheral arterial
disease
PCA  poorly compressible
arteries
Figure 1 Study Patients
Flow diagram of patients in our study. ABI  ankle-brachial index;
PAD  peripheral arterial disease; PCA  poorly compressible arteries.
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Survival in Patients With PCA January 24, 2012:400–7EMR using previously validated algorithms that have good
sensitivity and specificity compared with manual chart
abstraction (17). Smoking status and medication use were
ascertained using natural language processing as previously
described (18,19). Natural language processing was used to
discover drug “named-entity” mentions from clinical notes
since medications are often recorded in clinical notes as free
text. Laboratory data were obtained from the EMR using a
window of 1 year centered around the time of arterial
evaluation. Hypertension was considered present if there
were 2 BP readings of140/90 mm Hg within 3 months of
the date of arterial evaluation, or a prior diagnosis of
hypertension and current treatment with antihypertensive
medication. Diabetes was ascertained on the basis of fasting
plasma glucose 126 mg/dl, or random glucose 200
mg/dl, or hemoglobin A1c of 6.5%, or a prior diagnosis
nd use of oral hypoglycemic agent(s) or insulin. Comorbid
onditions such as coronary heart disease (CHD), cerebro-
ascular disease, heart failure, chronic kidney disease, ma-
ignancy, and chronic obstructive pulmonary disease were
scertained on the basis of the presence of relevant ICD-
-CM diagnosis and procedure codes for up to 6 months
ollowing the date of arterial evaluation (17). The presence
f critical limb ischemia in the study groups was ascertained
ased on ICD-9-CM diagnosis codes 440.22 to 440.24.
scertainment of survival. The follow-up period for each
atient was the time between the first arterial evaluation and
he earliest of date of death or final censoring date (Sep-
ember 30, 2009). Death was ascertained initially from the
ayo EMR. For persons who were not noted as being
eceased, we used the Accurint database (Seisint, West
alm Beach, Florida) to ascertain vital status. According to
he EMR and the Accurint database, the number of
ecedents was 4,365 (26% of the study cohort).
tatistical analysis. Demographic and physical character-
stics, laboratory values, cardiovascular risk factors, and
omorbid conditions were summarized as mean  standard
eviation for continuous variables and as frequencies and
ercentages for categorical variables. To assess the effect of
ge and sex on the prevalence of PCA, we performed
ogistic regression analyses. Differences in demographic and
linical characteristics between the 3 study groups were
ested with an analysis of covariance for continuous variables
nd by logistic regression for binary categorical variables,
djusting for age and sex. A p value of0.05 was considered
tatistically significant. We computed the Kaplan-Meier
urvival curves in the 3 groups of patients and compared
urvival using the 1-sample log-rank test.
We constructed a series of multivariable Cox proportional
azards models to estimate hazard ratios for death in the
CA patients compared with the normal ABI group and
AD groups, starting with an unadjusted model and then
djusting for age and sex, and then additionally for body
ass index (BMI), CHD, cerebrovascular disease, heart
ailure, diabetes, hypertension, chronic kidney disease, ma-
ignancy, chronic obstructive pulmonary disease, smoking, ond medication (statin and aspirin) use, and finally, for the
resence of critical limb ischemia. We assessed whether
nteractions existed between PCA and age and sex in
redicting hazard of dying compared with patients with a
ormal ABI and PAD. The multivariable Cox proportional
azards models were repeated in strata defined by any
ignificant interactions. We furthermore identified predic-
ors of survival and estimated the associated hazard ratios,
sing these same Cox proportional hazards models. To
ddress the possibility of a referral bias, we included
lmsted County residency as a predictor variable, and also
epeated the multivariable Cox proportional hazards models
tratified by Olmsted County residency. Finally, we assessed
hether the presence of abnormal arterial Doppler signals in
CA patients resulted in an additional increase in risk of
ortality and whether defining PAD as ABI 1.0 and
CA as ABI1.3 altered inferences. Statistical analysis was
erformed using SAS version 9.1 (SAS Institute, Cary,
orth Carolina).
esults
total of 22,859 patients underwent noninvasive lower
xtremity arterial evaluation between January 1, 1998, and
ecember 31, 2007. After applying the initial exclusion
riteria, 17,485 remained (Fig. 1). Additionally, we removed
atients with borderline low ABI (0.91 to 0.99) and
orderline high ABI (1.31 to 1.39) to arrive at the final
tudy sample of 16,493 patients (59% men, 98% non-
ispanic white, mean age 67.8  13.0 years). Of these,
,754 (29%) patients had a normal ABI (1.00 to 1.30) and
,958 patients (54%) had PAD. The latter included 158
atients with a normal ABI who had previously undergone
ower extremity revascularization for symptomatic PAD. A
ignificant proportion (17%, n  2,781) of patients had
CA (Table 1). The prevalence of critical limb ischemia was
ignificantly higher in patients with PCA than in patients
ith PAD (Table 1). Abnormal Doppler arterial waveforms
ere present in 1,976 (71%) of PCA patients. The propor-
ion of patients with normal ABI, PAD, and PCA among
en and women of various age ranges is shown in Figure 2.
he prevalence of PCA was higher in men (p 0.001) than
n women and increased with age (p  0.001) in both men
nd women. Patients with PAD or PCA were older than
he reference group. Other patient characteristics were
ompared after adjustment for age and sex (Table 1).
Pulse pressure was higher in the PCA and PAD groups
han the normal ABI group. Fasting serum glucose and
erum creatinine were highest in the PCA group. Among
ardiovascular risk factors, diabetes and hypertension were
ore prevalent in patients with PCA, whereas history of
moking was more common in patients with PAD (Table 1).
n the PCA group, a higher proportion of patients had
oexisting CHD, heart failure, and chronic kidney disease
han in the normal ABI and PAD groups (Table 1). On the
ther hand, the proportion of patients with cerebrovascular
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January 24, 2012:400–7 Survival in Patients With PCAdisease and chronic obstructive pulmonary disease was
highest in the PAD group (Table 1). The proportion of
patients on a statin medication or aspirin was higher in the
PCA and PAD groups than the normal ABI group, but was
not significantly different between PCA and PAD groups
(Table 1).
The mean follow-up for the entire group was 5.8  3.1
ears (median: 5.6 years, interquartile range: 3.2 to 8.3
ears). As of September 30, 2009, 4,365 (26%) patients had
ied; a greater proportion of patients with PCA died (n 
,123, 40%), followed by PAD patients (n  2,649, 30%),
nd patients with a normal ABI (n  593, 12%). The
stimated percent survival at 5 years was lowest in the PCA
roup (74%), followed by the PAD (79%) and normal ABI
86%) groups. Kaplan-Meier survival curves over 12 years of
ollow-up are shown in Figure 3. The curves start to
eparate early, and survival in PCA group was worse than in
he PAD and normal ABI groups.
We estimated the relative hazard of death in patients with
AD and PCA using multivariable Cox proportional haz-
rds regression. In the unadjusted model, compared with
atients with normal ABI, the hazard of death was 2.5-fold
igher in patients with PAD and 4.0-fold higher in patients
ith PCA (Table 2). In the model that adjusted for age, sex,
nd comorbid conditions, the hazard of death was 1.6-fold
igher in patients with PAD, and 2.0-fold higher in
Patient CharacteristicsTable 1 Patient Characteristics
Normal ABI
(n  4,754)
PAD
(n  8,958)
PCA
(n  2,781)
Age, yrs 63.0 14.3 69.3 11.7 71.3 12.1
Men 2,541 (53.5) 5,270 (58.8) 1,869 (67.2)
Olmsted County residents 618 (13.0) 1,027 (11.5) 302 (10.9)
BMI, kg/m2 29.7 6.7 28.4 5.7 29.9 6.7
Systolic BP, mm Hg 133 19 142 23 143 26
Diastolic BP, mm Hg 77 10 74 11 73 11
Pulse pressure, mm Hg 56 15 68 19 69 20
Plasma glucose, mg/dl 109.5 35.0 119.9 45.2 136.0 61.9
Serum creatinine, mg/dl 1.2 0.5 1.3 0.7 1.8 1.6
Ever smoked 3,457 (72.7) 7,773 (86.8) 2,011 (72.3)
Diabetes 862 (18.1) 2,542 (28.4) 1,628 (58.6)
Hypertension 2,491 (52.4) 6,578 (73.4) 2,171 (78.1)
Coronary heart disease 1,559 (32.8) 4,918 (54.9) 1,637(58.9)
Heart failure 343 (7.2) 1,233 (13.7) 738 (26.6)
Chronic kidney disease 198 (4.2) 635 (7.1) 531 (19.1)
Cerebrovascular disease 673 (14.2) 2,958 (33.0) 780 (28.1)
COPD 401 (8.4) 1,634 (18.3) 331 (11.9)
Malignancy 899 (18.9) 1,728 (19.3) 611 (22.0)
Critical limb ischemia — 1,657 (18.5) 1,029 (37)
Statin use 1,282 (27.0) 3,382 (37.8) 1,024 (36.8)
Aspirin use 1,677 (35.28) 4,167 (46.5) 1,270 (45.7)
Values are mean SD and n (%). Differences in age and sex between study groups were significant
at p 0.001. Age- and sex-adjusted differences in the remaining patient characteristics were also
ignificant at p  0.001, except for Olmsted County residency (p  0.007).
ABI  ankle brachial index; BMI  body mass index; BP  blood pressure; COPD  chronic
obstructive pulmonary disease; PAD  peripheral arterial disease; PCA  poorly compressible
arteries.atients with PCA than those with normal ABI (Table 2).hen we compared patients with PCA to patients with
AD, the former had 60% higher hazard of death (hazard
atio [HR]: 1.6, 95% confidence interval [CI]: 1.5 to 1.7) in
he unadjusted model and 30% higher hazard of death (HR:
.3, 95% CI: 1.2 to 1.4) after adjustment for age sex and
omorbid conditions (Table 2). The presence of PCA was
ssociated with increased hazard of death even after addi-
ional adjustment for critical limb ischemia (Table 2). We
ound significant interactions between presence of PCA and
ex in influencing the hazard of death compared with
atients with a normal ABI (p  0.001) and PAD (p 
.007). We therefore performed analyses stratified by sex.
ompared with patients with normal ABI, the hazard of
eath associated with PCA was greater in women (2.6) than
n men (1.7) (Table 2). Compared with patients with PAD,
he hazard of death associated with PCA was also greater in
omen (1.5) than in men (1.3) (Table 2). Olmsted County
esidency was associated with a greater hazard of death,
onsistent with a modest referral bias. However, in analyses
tratified by Olmsted County residency, the hazard ratios
ssociated with PCA and other predictor variables were
imilar in magnitude (Table 3).
In the fully adjusted model, factors in addition to PCA
hat were associated with an increased hazard of dying were
ypertension, diabetes, history of smoking, CHD, cerebro-
ascular disease, heart failure, chronic obstructive pulmonary
isease, chronic kidney disease, and malignancy (Table 3).
higher BMI, and statin and aspirin use were associated
ith a reduced hazard of death (Table 3). In patients with
CA, the presence of abnormal Doppler arterial waveforms
as associated with an incremental hazard of death inde-
endent of age, sex, cardiovascular risk factors, comorbid
onditions, and medication use (HR: 1.55, 95% CI: 1.31 to
.83; p0.0001). When we used criteria for PAD as ABI
Figure 2 Age and Sex Distribution in the 3 Study Groups
The proportion of patients with normal ABI, PAD, and PCA among men and
women of various age ranges. The prevalence of PCA was higher in men
(p  0.001) than in women and increased with age (p  0.001) in both men
and women. Abbreviations as in Figure 1.
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Survival in Patients With PCA January 24, 2012:400–71.0 and for PCA as ABI 1.3, the fully adjusted hazards
f death associated with PAD and PCA, compared with an
BI of 1.0 to 1.3 were 1.58 (95% CI: 1.44 to 1.74) and 1.98
95% CI: 1.76 to 2.20), respectively, similar to when using
he initial definitions for PAD and PCA.
When analyses were repeated using the higher of the 2
nkle pressures to calculate the ABI, the inferences were
nchanged. The results of these analyses are summarized in
he Online Appendix.
iscussion
n this historical cohort study of patients referred for a
oninvasive arterial evaluation, patients who met criteria for
CA had significantly lower survival than patients with
AD and those with normal ABI. Among patients with
CA, 40% died by the end of the study period, a signifi-
antly higher proportion than in patients with PAD (30%)
nd normal ABI (12%). Having PCA was associated with
.0- and 1.6-fold unadjusted higher hazard of death than
he normal ABI and PAD groups, respectively. The higher
isk of death appeared to be due in part to greater age and
igher prevalence of comorbid conditions and cardiovascu-
ar risk factors. After adjustment for age, sex, cardiovascular
isk factors, comorbid conditions, and medication use, patients
ith PCA were at a 2.0- and 1.3-fold higher risk of death than
he normal ABI and PAD groups, respectively. The hazard of
eath due to PCA was higher in women than in men.
Three previous cohort studies showed a U-shaped asso-
iation between ABI and survival (11–13). These studies
sed different criteria to label patients as having normal
BI, PAD, and PCA. The Strong Heart Study (11)
included 4,393 American Indians, grouped into low
(0.90), normal (0.90 to 1.40), and high ABI (1.40)
Figure 3 Kaplan-Meier Survival Curves in the 3 Study Groups
The number of patients in each study group at 1, 5, and 10 years of follow-up arecategories. Participants with borderline-low and borderline-high ABI were included in the “reference category.” During
a mean follow-up of 8.3  2 years, 1,022 participants died.
The adjusted HR of death was 1.7 in the PAD group and
1.8 in the high ABI group (11). In the Cardiovascular
Health Study (12), 5,748 Medicare-eligible adults were
followed for a mean of 11.1 years. The adjusted HR of
death increased at ABI values above and below the normal
range (1.00 to 1.30). Compared with the normal ABI
group, the HR of death in the high ABI (1.40) group was
1.60. However, this study excluded patients in whom ABI
could not be calculated, and therefore may have included
only a “milder” form of PCA (12). In the MESA (Multi-
ethnic Study of Atherosclerosis) (13), 6,647 non-Hispanic
white, African-American, Hispanic, and Chinese men and
women age 45 to 84 years without history of myocardial
infarction or stroke, underwent measurement of ABI. After
adjustment for both traditional and newer cardiovascular
risk factors, hazard ratios for a low (1.0) and high (1.40)
ABI were 1.77 and 1.85, respectively.
In contrast to these 3 studies (11–13) in which survival of
patients with high ABI was similar to those with PAD, we
found that the adjusted HR for death was higher in patients
with PCA than those with PAD. A cross-sectional study of
7,155 patients age 50 years from 350 primary care sites
found those with ABI 1.40 at higher odds for foot ulcer,
neuropathy, heart failure, and stroke after adjustment for
traditional risk factors, compared with those with normal
ABI (20). Our results confirm that both PAD and PCA are
associated with reduced survival compared with patients
with a normal ABI, and in addition, demonstrate that
having PCA carries 30% (adjusted) higher risk of death than
having PAD. This is an important finding, given that the
presence of PAD in itself is associated with a relatively poor
. Abbreviations as in Figure 1.listedprognosis (21–24). Olmsted County residency was associ-
405JACC Vol. 59, No. 4, 2012 Arain et al.
January 24, 2012:400–7 Survival in Patients With PCAated with a modestly greater hazard of death in our study
cohort, suggesting a “healthy person” referral bias. In other
words, patients from outside of the Olmsted County were
“healthier” and able to travel to Rochester, Minnesota, for
Hazard Ratio of Death Associated With the PresCompared With the Normal ABI and PAD GroupTable 2 Hazard Ratio of Death Associated WCompared With the Normal ABI and
Normal
Model A
All patients, n  16,493 1.0
Men, n  9,680 1.0
Women, n  6,813 1.0
Olmsted County patients, n  1,947 1.0
Non-Olmsted County patients, n  14,546 1.0
Model B
All patients 1.0
Men 1.0
Women 1.0
Olmsted County patients 1.0
Non-Olmsted County patients 1.0
Model C
All patients 1.0
Men 1.0
Women 1.0
Olmsted County patients 1.0
Non-Olmsted County patients 1.0
Model D
All patients 1.0
Men 1.0
Women 1.0
Olmsted County patients 1.0
Non-Olmsted County patients 1.0
Model A: unadjusted; Model B: adjusted for age and sex; Model C: ad
disease, cerebrovascular disease, congestive heart failure, diabete
pulmonary disease, smoking, statin use, and aspirin use. Model D: a
sex-stratified models were not adjusted for sex.
Abbreviations as in Table 1.
Variables Associated With Relative Hazard RatiTable 3 Variables Associated With Relative
All Patients
Age (per decade increase) 1.50 (1.45–1.55)
Male 1.11 (1.04–1.18)
BMI (5 kg/m2 increase) 0.91 (0.89–0.94)
Ever smoked 1.13 (1.04–1.23)
Diabetes 1.53 (1.43–1.63)
Hypertension 1.14 (1.06–1.24)
Coronary heart disease 1.32 (1.23–1.41)
Heart failure 2.13 (1.98–2.30)
Chronic kidney disease 1.83 (1.68–1.99)
Cerebrovascular disease 1.18 (1.10–1.26)
COPD 1.52 (1.42–1.64)
Malignancy 1.50 (1.40–1.60)
Statin use 0.70 (0.65–0.75)
Aspirin use 0.92 (0.86–0.98)
Olmsted County residency 1.21 (1.11–1.32)Abbreviations as in Table 1.further evaluation of leg symptoms. However, in analyses
stratified by Olmsted County residency, the relative hazards
associated with the predictor variables, including the pres-
ence of PCA, were similar.
of PCA,he resence of PCA,
Groups
Hazard Ratio (95% Confidence Interval)
PAD PCA PCA vs. PAD
2.5 (2.3–2.7) 4.0 (3.6–4.4) 1.6 (1.5–1.7)
2.0 (1.8–2.3) 3.0 (2.7–3.4) 1.5 (1.4–1.6)
3.3 (2.8–3.8) 6.0 (5.1–7.1) 1.9 (1.7–2.1)
2.3 (1.9–2.9) 4.6 (3.5–5.9) 2.0 (1.6–2.3)
2.5 (2.3–2.8) 3.9 (3.5–4.4) 1.6 (1.5–1.7)
1.9 (1.8–2.1) 2.9 (2.6–3.3) 1.5 (1.4–1.6)
1.7 (1.5–1.9) 2.4 (2.2–2.8) 1.4 (1.3–1.5)
2.3 (2.0–2.7) 4.2 (3.5–5.0) 1.7 (1.5–2.0)
1.6 (1.3–2.0) 2.8 (2.1–3.6) 1.8 (1.5–2.1)
2.0 (1.8–2.2) 3.0 (2.7–3.4) 1.5 (1.4–1.6)
1.6 (1.5–1.8) 2.0 (1.8–2.3) 1.3 (1.2–1.4)
1.3 (1.5–1.6) 1.7 (1.5–2.0) 1.3 (1.2–1.4)
1.9 (1.6–2.2) 2.7 (2.2–3.4) 1.4 (1.2–1.6)
1.3 (1.0–1.6) 1.8 (1.4–2.5) 1.4 (1.1–1.7)
1.7 (1.5–1.9) 2.1 (1.9–2.4) 1.3 (1.2–1.4)
1.5 (1.4–1.6) 1.8 (1.6–2.0) 1.2 (1.1–1.3)
1.4 (1.2–1.5) 1.5 (1.3–1.7) 1.2 (1.1–1.3)
1.7 (1.5–2.1) 2.5 (2.0–3.1) 1.3 (1.2–1.5)
1.2 (0.9–1.5) 1.6 (1.1–2.2) 1.3 (1.0–1.5)
1.6 (1.4–1.7) 1.9 (1.6–2.1) 1.2 (1.1–1.3)
or age, sex, body mass index, systolic blood pressure, coronary heart
rtension, chronic kidney disease, malignancy, chronic obstructive
for Model C variables plus presence of critical limb ischemia. The
yingrd Ratio of Dying
rd Ratio (Confidence Interval)
d County Patients Non-Olmsted County Patients
64 (1.51–1.77) 1.48 (1.43–1.53)
24 (1.05–1.46) 1.08 (1.01–1.16)
92 (0.85–0.99) 0.91 (0.89–0.94)
99 (0.82–1.21) 1.17 (1.07–1.28)
64 (1.39–1.94) 1.51 (1.40–1.62)
23 (0.97–1.56) 1.14 (1.05–1.24)
11 (0.91–1.35) 1.35 (1.25–1.45)
25 (1.87–2.71) 2.14 (1.97–2.31)
74 (1.41–2.14) 1.84 (1.68–2.03)
19 (1.00–1.40) 1.17 (1.09–1.25)
42 (1.18–1.71) 1.55 (1.44–1.68)
34 (1.14–1.58) 1.53 (1.43–1.65)
71 (0.59–0.85) 0.70 (0.65–0.76)
14 (0.96–1.35) 0.88 (0.83–0.95)
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Survival in Patients With PCA January 24, 2012:400–7In a study (15) of 403 hospitalized diabetic patients, the
presence of PCA and abnormal Doppler, but not PCA
alone, was associated with a higher risk of cardiovascular
events. By contrast, the presence of PCA with normal
Doppler waveforms in our study was associated with in-
creased risk of mortality compared with those with normal
ABI (fully adjusted HR: 1.4, 95% CI: 1.2 to 1.6) but not
when compared with patients with PAD (fully adjusted
HR: 0.9, 95% CI: 0.8 to 1.1). The presence of abnormal
Doppler in patients with PCA was associated with a
significant increment in the risk of death, suggesting that
concomitant atherosclerosis adds to the risk due to medial
arterial calcification. Whether the presence of PCA is
merely a marker of increased risk or directly contributes to
increased mortality is unknown.
One potential mechanism of increased risk is greater
arterial stiffness in patients with PCA. We found systolic
BP and pulse pressure to be higher in the PCA and PAD
groups than in normal ABI group. In MESA (6), partici-
pants with PCA had greater left ventricular mass than
patients with the normal or low ABI. The authors postu-
lated that medial artery calcification leads to increased
arterial stiffness and increased left ventricular afterload,
thereby increasing left ventricular mass (6). Consistent with
this hypothesis, we previously demonstrated that serum
N-terminal pro-B-type natriuretic peptide levels are signif-
icantly higher in patients with PCA than in patients with
normal ABI and those with PAD (25). An additional
mechanism could be the high prevalence of critical limb
ischemia in patients with PCA. However, even after addi-
tional adjustment for the presence of critical limb ischemia,
patients with PCA had a higher hazard of dying than
patients with or without PAD.
Our study has several important clinical implications.
First, a substantial proportion of patients (17% in the
present study) referred for noninvasive lower extremity
arterial evaluation had PCA. The prevalence of PCA is
likely to increase as a result of aging and increased preva-
lence of diabetes, highlighting the need for increased aware-
ness of this entity (26). Second, the presence of PCA in
older adults indicates increased risk of mortality and moti-
vates further investigation to identify factors whose modi-
fication would improve survival. Finally, among the 3
groups in our study, patients with PCA had the highest
prevalence of diabetes, heart failure, and chronic kidney
disease. Together with prior studies that have reported an
increased risk of amputation and poor quality of life in
patients (20,27–29), these data indicate a high level of
comorbidity and healthcare burden associated with PCA.
Identifying risk factors for medial arterial calcification and
treating such factors is important, given that treatment
options for vascular calcification are limited (30).
Strengths and limitations. A strength of the present study
s the large sample of patients who underwent standardized
valuation in an accredited noninvasive vascular laboratory.
o the best of our knowledge, the 2,781 patients with PCAcomprise the largest reported cohort of such patients to
date. Although we attempted to limit referral bias by
excluding patients who lived outside of a 500-mile radius of
our medical center, and also performed sensitivity analyses
using Olmsted County residency as a stratification variable,
our survival estimates need to be validated in additional
studies. The study cohort was almost entirely non-Hispanic
white, and whether our findings can be generalized to other
racial and ethnic groups needs further study. We did not
have imaging studies available to confirm medial arterial
calcification in patients with PCA, nor did we have infor-
mation on all adverse cardiovascular events or the cause of
death.
Conclusions and Future Directions
A significant proportion of patients referred for noninvasive
lower extremity arterial evaluation had PCA, and survival in
such patients was lower than in those with a normal ABI,
and even lower than in patients with PAD. After adjusting
for age, sex, cardiovascular risk factors, comorbid condi-
tions, and medications, the hazard of dying in the PCA
group was 2.0-fold higher than in those with normal ABI
and 1.3-fold lower than those with ABI 0.90. The hazard
of dying associated with PCA was higher in women than in
men. There was an increased prevalence of comorbid
conditions in patients with PCA, especially diabetes, heart
failure, and chronic kidney disease. However, other as yet
unidentified factors may contribute to reduced survival in
patients with PCA. Further investigation is needed to
identify mechanisms that lead to development of PCA
(30–36), identify mediators of poor survival, and explore
treatment options to improve survival in these high-risk
patients.
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